WO2009036084A3 - Adhering troches with topically active ingredients for treatment of throat, esophagus, and stomach - Google Patents

Adhering troches with topically active ingredients for treatment of throat, esophagus, and stomach Download PDF

Info

Publication number
WO2009036084A3
WO2009036084A3 PCT/US2008/075885 US2008075885W WO2009036084A3 WO 2009036084 A3 WO2009036084 A3 WO 2009036084A3 US 2008075885 W US2008075885 W US 2008075885W WO 2009036084 A3 WO2009036084 A3 WO 2009036084A3
Authority
WO
WIPO (PCT)
Prior art keywords
adhering
throat
esophagus
stomach
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/075885
Other languages
French (fr)
Other versions
WO2009036084A2 (en
Inventor
Jeffrey T Haley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orahealth LLC
Original Assignee
Orahealth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orahealth LLC filed Critical Orahealth LLC
Priority to EP08799420A priority Critical patent/EP2200592A2/en
Priority to US12/735,017 priority patent/US20100285098A1/en
Priority to JP2010524245A priority patent/JP2010539096A/en
Priority to CN200880106184A priority patent/CN101801353A/en
Publication of WO2009036084A2 publication Critical patent/WO2009036084A2/en
Publication of WO2009036084A3 publication Critical patent/WO2009036084A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A method for combating unwanted conditions downstream of the mouth with adhering troches. A method to treat or reduce replication of a virus in throat tissues by releasing an anti-viral from an adhering disc. A method to treat sore throat with time release of Glycyrrhiza extract or collagen from an adhering disc. A method to treat sore throat with topically applied cobalamin. An adhering troche that releases antacid, alginate, bismuth subsalicylate, soluble zinc, such as zinc gluconate, bioactive vitamin B12 (methylcobalamin), antibiotic, or anti-viral. A method to combat bacterial effects downstream of the mouth with topically applied xylitol.
PCT/US2008/075885 2007-09-11 2008-09-10 Adhering troches with topically active ingredients for treatment of throat, esophagus, and stomach Ceased WO2009036084A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP08799420A EP2200592A2 (en) 2007-09-11 2008-09-10 Adhering troches with topically active ingredients for treatment of throat, esophagus, and stomach
US12/735,017 US20100285098A1 (en) 2007-09-11 2008-09-10 Adhering troches with santacid for treatment of throat esophagus and stomach
JP2010524245A JP2010539096A (en) 2007-09-11 2008-09-10 Adhesive lozenges that release topically active ingredients for the treatment of throat, esophagus and stomach
CN200880106184A CN101801353A (en) 2007-09-11 2008-09-10 Adhering troches with topically active ingredients for treatment of throat, esophagus, and stomach

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US99345707P 2007-09-11 2007-09-11
US60/993,457 2007-09-11
US99575407P 2007-09-27 2007-09-27
US60/995,754 2007-09-27
US6306108P 2008-01-30 2008-01-30
US61/063,061 2008-01-30

Publications (2)

Publication Number Publication Date
WO2009036084A2 WO2009036084A2 (en) 2009-03-19
WO2009036084A3 true WO2009036084A3 (en) 2009-05-14

Family

ID=40452805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/075885 Ceased WO2009036084A2 (en) 2007-09-11 2008-09-10 Adhering troches with topically active ingredients for treatment of throat, esophagus, and stomach

Country Status (5)

Country Link
US (1) US20100285098A1 (en)
EP (1) EP2200592A2 (en)
JP (1) JP2010539096A (en)
CN (1) CN101801353A (en)
WO (1) WO2009036084A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549842B2 (en) 2011-02-04 2017-01-24 Joseph E. Kovarik Buccal bioadhesive strip and method of treating snoring and sleep apnea
US8701671B2 (en) 2011-02-04 2014-04-22 Joseph E. Kovarik Non-surgical method and system for reducing snoring
WO2011126537A2 (en) * 2010-04-05 2011-10-13 Orahealth Corporation Oral adhering compositions that apply rhizophora mangle extract in the mouth
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US9987224B2 (en) 2011-02-04 2018-06-05 Joseph E. Kovarik Method and system for preventing migraine headaches, cluster headaches and dizziness
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US11523934B2 (en) 2011-02-04 2022-12-13 Seed Health, Inc. Method and system to facilitate the growth of desired bacteria in a human's mouth
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US10687975B2 (en) 2011-02-04 2020-06-23 Joseph E. Kovarik Method and system to facilitate the growth of desired bacteria in a human's mouth
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US10086018B2 (en) 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
EP2704799A4 (en) 2011-05-06 2014-10-29 Lankenau Inst Medical Res COMPOSITIONS AND METHODS FOR THE PREVENTION OF SOPHAGE CANCER
US9789061B2 (en) * 2012-02-19 2017-10-17 Orahealth Corp. Acacia gum adhesive with calcium carbonate for oral adhering discs
CN105451724A (en) * 2013-08-08 2016-03-30 奥拉黑尔斯公司 Reducing reflux while sleeping by stimulating saliva with adhering troches
WO2015056196A1 (en) * 2013-10-16 2015-04-23 Orahealth Corporation Treating mucosal lesions with hyaluronan delivered from an adhering troche
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
EP3160451B1 (en) 2014-06-27 2021-04-07 Farm To Farma, Inc. Buccal and sublingual cannabinoid formulations and method of making the same
WO2016128972A1 (en) 2015-02-09 2016-08-18 Entera Bio Ltd. Formulations for oral administration of active agents with controlled absorption profile
US12239706B2 (en) 2015-11-30 2025-03-04 Seed Health, Inc. Method and system for protecting monarch butterflies from pesticides
MX2019001850A (en) 2016-08-17 2019-05-15 Entera Bio Ltd Formulations for oral administration of active agents.
US20180296466A1 (en) * 2017-04-16 2018-10-18 Orahealth Corp. Gelatin and compression binder for use in oral adhering discs
US11612564B2 (en) 2018-04-21 2023-03-28 Quest Products, Llc Bilayer adhering lozenge effective to mask undesirable flavor
WO2020055547A2 (en) 2018-08-18 2020-03-19 Seed Health, Inc. Methods and compositions for honey bee health
CN112730658A (en) * 2020-12-18 2021-04-30 卓和药业集团有限公司 Method for analyzing dissolution curve of mecobalamin tablets
US12233158B2 (en) 2021-06-04 2025-02-25 Quest Products, Llc Orally adhering lozenges containing soluble dietary fiber
US12485089B1 (en) 2025-03-13 2025-12-02 Quest Products, Llc Adhering lozenge with high amount of sparsely soluble active ingredient

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070048369A1 (en) * 2005-08-26 2007-03-01 National Starch And Chemical Investment Holding Corporation Mucosal delivery tablet
US20070104783A1 (en) * 2001-02-28 2007-05-10 Axiomedic Ltd. Double-Layered Absorbable Solid Compositions for the Topical Treatment of Oral Mucosal Disorders
US20070190139A1 (en) * 2006-02-13 2007-08-16 Intelgenx Corp. Delayed release pharmaceutical oral dosage form and method of making same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4163777A (en) * 1977-04-29 1979-08-07 Lewis/Howe Company Controlled antacid delivery form and method of treatment therewith
JPS5562012A (en) * 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US5002970A (en) * 1981-07-31 1991-03-26 Eby Iii George A Flavor masked ionizable zinc compositions for oral absorption
JP2000063268A (en) * 1998-06-12 2000-02-29 Lion Corp Oral mucosa-attached sustained-release tablet and therapeutic agent for periodontal disease
US20070084369A1 (en) * 2005-09-26 2007-04-19 Jsr Corporation Flexographic printing plate and process for production thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070104783A1 (en) * 2001-02-28 2007-05-10 Axiomedic Ltd. Double-Layered Absorbable Solid Compositions for the Topical Treatment of Oral Mucosal Disorders
US20070048369A1 (en) * 2005-08-26 2007-03-01 National Starch And Chemical Investment Holding Corporation Mucosal delivery tablet
US20070190139A1 (en) * 2006-02-13 2007-08-16 Intelgenx Corp. Delayed release pharmaceutical oral dosage form and method of making same

Also Published As

Publication number Publication date
WO2009036084A2 (en) 2009-03-19
EP2200592A2 (en) 2010-06-30
US20100285098A1 (en) 2010-11-11
JP2010539096A (en) 2010-12-16
CN101801353A (en) 2010-08-11

Similar Documents

Publication Publication Date Title
WO2007115282A3 (en) Use of ketogenic compounds for treatment of age-associated memory impairment
WO2009040445A3 (en) Arabinoxylo-oligosaccharides useful against gastrointestinal infections
US20100285098A1 (en) Adhering troches with santacid for treatment of throat esophagus and stomach
WO2007130886A3 (en) Nutritional supplement and use thereof
AR071968A1 (en) USE OF AN OLIGOSACARIDO IN THE TREATMENT OF INTESTINAL INFLAMMATION
WO2008149802A1 (en) Anti-fatigue agent and oral composition each comprising andrographolide as active ingredient
BRPI0418681A (en) a dietary supplement for the treatment and prevention of diseases of the digestive system and diseases related to the digestive system and method of production and administration thereof.
SI2268292T1 (en) Method and compositions for treatment of cancer
CN102281887A (en) Compositions for the treatment of gastro-esofageal reflux disease (GERD)
Kim et al. Effects of Scutellariae radix and Aloe vera gel extracts on immunoglobulin E and cytokine levels in atopic dermatitis NC/Nga mice
Cem et al. Helicobacter pylori eradication with beta carotene, ascorbic acid and allicin
IL304064A (en) Methods and compositions for treating thyroid-related medical conditions with reduced folates
US20250255926A1 (en) Gingerol compositions and related methods
WO2007087623A3 (en) Methods and compositions for treating feline hyperthyroidism
WO2008058210A3 (en) Local administration of gallium compositions to treat pain
Chansue et al. The in vitro antibacterial activity and ornamental fish toxicity of the water extract of Indian almond leaves (Terminalia catappa Linn.)
WO2010023572A4 (en) Herbal extract as sensitivity enhancer toward insulin and antidiabetes
WO2010079910A3 (en) Eyesight-protecting composition containing functional components having preventive and therapeutic efficacy in diabetes or diabetes complications
WO2008018111A3 (en) Composition containing cranberry (vaccinium macrocarpon) and lactoferrin for the prevention and treatment of urinary tract infections
Rohdewald et al. In vitro inhibition of helicobacter pylori growth and adherence to gastric mucosal cells by Pycnogenol®
HRP20130925T1 (en) NUTRITION SUPPLEMENT FOR MEN'S SEXUAL FUNCTIONS STIMULATION
Yarnell et al. Antiadhesion herbs
BR112012011316A2 (en) tivozanib and temsirolimus in combination
WO2022029736A1 (en) Multi -component composition comprising ganoderma lucidum extract, panax extract, vitamins, zinc and bacterial strains and use thereof in the prevention and treatment of flu symptoms and in the increase in immune defences
Onyeka et al. Gastroprotective effects of Methanol leaf extract of Desmodium velutinum (Fabaceae) and honey on ethanolinduced gastric ulcer in albino rat: The concept of combination therapy

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880106184.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08799420

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2010524245

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1622/DELNP/2010

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008799420

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12735017

Country of ref document: US